Skip to main
PLRX

PLRX Stock Forecast & Price Target

PLRX Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Pliant Therapeutics Inc has established a robust scientific foundation that positions it competitively within the evolving biotech landscape, particularly through its innovative integrin-targeted therapies. The positive Phase I results for its lead candidate, PLN-101095, specifically the substantial increase in IFN-γ among responders and its well-tolerated profile, bolster the prospects for further development and market entry. Furthermore, the experienced management team adeptly handles regulatory interactions, driving confidence that potential commercial risks are mitigated by their track record in successful product launches.

Bears say

Pliant Therapeutics Inc. faces significant challenges associated with the inherent risks in clinical development, particularly regarding potential failures in its lead product candidate, PLN-101095, which targets integrins for solid tumors. The historical difficulties encountered in developing integrin inhibitors for conditions such as idiopathic pulmonary fibrosis (IPF) heighten concerns about the likelihood of clinical setbacks that could jeopardize the company's drug pipeline. Additionally, the company is subject to regulatory uncertainties that could impact its development processes, exacerbating the risks associated with its financial outlook due to a diminished cash position and increased share counts.

PLRX has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pliant Therapeutics (PLRX) Forecast

Analysts have given PLRX a Hold based on their latest research and market trends.

According to 3 analysts, PLRX has a Hold consensus rating as of Mar 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pliant Therapeutics (PLRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.